CliffBio
biologic

Buminate, Flexbumin

Albumin (Human)

Loss of exclusivityMarch 1966projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameBuminate, Flexbumin
Active ingredientAlbumin (Human)
Strength20G/100ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 1954
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Buminate, Flexbumin patent cliff — loss of exclusivity March 1966 | CliffBio